Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty

TL;DR

Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty Goldman Sachs’ Alternatives Arm Buys Stake in Swiss AI Firm BLP The call comes down to one idea. Philip Morris is no longer just a cigarette company; it is becoming a smoke-free business. That shift could drive a higher-quality earnings profile if execution holds.